Fig. 1: Participant flow chart. | npj Drug Discovery

Fig. 1: Participant flow chart.

From: Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection trial

Fig. 1

All 34 potential participants were screened, of whom 28 were selected for inclusion and six were added to a reserve pool of eligible participants to fill in when selected participants were no longer eligible (i.e., had cold symptoms, n = 1) or withdrew before randomization (n = 3). All randomized participants completed follow-up, defined as completed sample and data collection up to the last study day (25 days post inoculation). Potential transmission was defined as contact between an RSV-positive participant and their household member, who reported that symptoms started <7 days after the participant was inoculated. Abbreviations: RSV+ RSV positive, RSV− RSV negative. The figure was created using Microsoft Visio Drawing.

Back to article page